SrasV1, PascalFrancis, Corpus, bibRecord, 000299

Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge

Identifieur interne : 000299 ( PascalFrancis/Corpus ); précédent : 000298; suivant : 000300

Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge

Auteurs : Barry Rockx ; Davide Corti ; Eric Donaldson ; Timothy Sheahan ; Konrad Stadler ; Antonio Lanzavecchia ; Ralph Baric

Source :

Journal of virology [ 0022-538X ] ; 2008.

RBID : Pascal:08-0181246

Descripteurs français

Pascal (Inist)
- Homme, Coronavirus, Protection croisée, Anticorps neutralisant, Anticorps monoclonal, Aigu, Virologie.

English descriptors

KwdEn :
- Acute, Coronavirus, Cross protection, Human, Monoclonal antibody, Neutralizing antibody, Virology.

Abstract

Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in 2002, and detailed phylogenetic and epidemiological analyses have suggested that it originated from animals. The spike (S) glycoprotein has been identified as a major component of protective immunity, and 23 different amino acid changes were noted during the expanding epidemic. Using a panel of SARS-CoV recombinants bearing the S glycoproteins from isolates representing the zoonotic and human early, middle, and late phases of the epidemic, we identified 23 monoclonal antibodies (MAbs) with neutralizing activity against one or multiple SARS-CoV spike variants and determined the presence of at least six distinct neutralizing profiles in the SARS-CoV S glycoprotein. Four of these MAbs showed cross-neutralizing activity against all human and zoonotic S variants in vitro, and at least three of these were mapped in distinct epitopes using escape mutants, structure analyses, and competition assays. These three MAbs (S109.8, S227.14, and S230.15) were tested for use in passive vaccination studies using lethal SARS-CoV challenge models for young and senescent mice with four different homologous and heterologous SARS-CoV S variants. Both S227.14 and S230.15 completely protected young and old mice from weight loss and virus replication in the lungs for all viruses tested, while S109.8 completely protected mice from weight loss and clinical signs in the presence of viral titers. We conclude that a single human MAb can confer broad protection against lethal challenge with multiple zoonotic and human SARS-CoV isolates, and we identify a robust cocktail formulation that targets distinct epitopes and minimizes the likely generation of escape mutants.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0022-538X`
A03		`1`		`@0 J. virol.`
A05				`@2 82`
A06				`@2 7`
A08	`01`	`1`	`ENG`	`@1 Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge`
A11	`01`	`1`		`@1 ROCKX (Barry)`
A11	`02`	`1`		`@1 CORTI (Davide)`
A11	`03`	`1`		`@1 DONALDSON (Eric)`
A11	`04`	`1`		`@1 SHEAHAN (Timothy)`
A11	`05`	`1`		`@1 STADLER (Konrad)`
A11	`06`	`1`		`@1 LANZAVECCHIA (Antonio)`
A11	`07`	`1`		`@1 BARIC (Ralph)`
A14	`01`			`@1 Department of Epidemiology, University of North Carolina @2 Chapel Hill, North Carolina @3 USA @Z 1 aut. @Z 7 aut.`
A14	`02`			`@1 Institute for Research in Biomedicine @2 Bellinzona @3 CHE @Z 2 aut. @Z 6 aut.`
A14	`03`			`@1 Department of Microbiology and Immunology, University of North Carolina @2 Chapel Hill, North Carolina @3 USA @Z 3 aut. @Z 4 aut. @Z 7 aut.`
A14	`04`			`@1 Novartis Vaccines, Via Fiorentina 1 @2 53100 Siena @3 ITA @Z 5 aut.`
A20				`@1 3220-3235`
A21				`@1 2008`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 13592 @5 354000183723680050`
A44				`@0 0000 @1 © 2008 INIST-CNRS. All rights reserved.`
A45				`@0 57 ref.`
A47	`01`	`1`		`@0 08-0181246`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of virology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in 2002, and detailed phylogenetic and epidemiological analyses have suggested that it originated from animals. The spike (S) glycoprotein has been identified as a major component of protective immunity, and 23 different amino acid changes were noted during the expanding epidemic. Using a panel of SARS-CoV recombinants bearing the S glycoproteins from isolates representing the zoonotic and human early, middle, and late phases of the epidemic, we identified 23 monoclonal antibodies (MAbs) with neutralizing activity against one or multiple SARS-CoV spike variants and determined the presence of at least six distinct neutralizing profiles in the SARS-CoV S glycoprotein. Four of these MAbs showed cross-neutralizing activity against all human and zoonotic S variants in vitro, and at least three of these were mapped in distinct epitopes using escape mutants, structure analyses, and competition assays. These three MAbs (S109.8, S227.14, and S230.15) were tested for use in passive vaccination studies using lethal SARS-CoV challenge models for young and senescent mice with four different homologous and heterologous SARS-CoV S variants. Both S227.14 and S230.15 completely protected young and old mice from weight loss and virus replication in the lungs for all viruses tested, while S109.8 completely protected mice from weight loss and clinical signs in the presence of viral titers. We conclude that a single human MAb can confer broad protection against lethal challenge with multiple zoonotic and human SARS-CoV isolates, and we identify a robust cocktail formulation that targets distinct epitopes and minimizes the likely generation of escape mutants.
C02	`01`	`X`		`@0 002A05C10`
C02	`02`	`X`		`@0 002A05C07`
C03	`01`	`X`	`FRE`	`@0 Homme @5 01`
C03	`01`	`X`	`ENG`	`@0 Human @5 01`
C03	`01`	`X`	`SPA`	`@0 Hombre @5 01`
C03	`02`	`X`	`FRE`	`@0 Coronavirus @2 NW @5 02`
C03	`02`	`X`	`ENG`	`@0 Coronavirus @2 NW @5 02`
C03	`02`	`X`	`SPA`	`@0 Coronavirus @2 NW @5 02`
C03	`03`	`X`	`FRE`	`@0 Protection croisée @5 05`
C03	`03`	`X`	`ENG`	`@0 Cross protection @5 05`
C03	`03`	`X`	`SPA`	`@0 Protección cruzada @5 05`
C03	`04`	`X`	`FRE`	`@0 Anticorps neutralisant @5 06`
C03	`04`	`X`	`ENG`	`@0 Neutralizing antibody @5 06`
C03	`04`	`X`	`SPA`	`@0 anticuerpo neutralizante @5 06`
C03	`05`	`X`	`FRE`	`@0 Anticorps monoclonal @5 07`
C03	`05`	`X`	`ENG`	`@0 Monoclonal antibody @5 07`
C03	`05`	`X`	`SPA`	`@0 Anticuerpo monoclonal @5 07`
C03	`06`	`X`	`FRE`	`@0 Aigu @5 08`
C03	`06`	`X`	`ENG`	`@0 Acute @5 08`
C03	`06`	`X`	`SPA`	`@0 Agudo @5 08`
C03	`07`	`X`	`FRE`	`@0 Virologie @5 09`
C03	`07`	`X`	`ENG`	`@0 Virology @5 09`
C03	`07`	`X`	`SPA`	`@0 Virología @5 09`
C07	`01`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`01`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`01`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`02`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`02`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`03`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`03`	`X`	`SPA`	`@0 Virus @2 NW`
N21				`@1 112`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 08-0181246 INIST
ET :	Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge
AU :	ROCKX (Barry); CORTI (Davide); DONALDSON (Eric); SHEAHAN (Timothy); STADLER (Konrad); LANZAVECCHIA (Antonio); BARIC (Ralph)
AF :	Department of Epidemiology, University of North Carolina/Chapel Hill, North Carolina/Etats-Unis (1 aut., 7 aut.); Institute for Research in Biomedicine/Bellinzona/Suisse (2 aut., 6 aut.); Department of Microbiology and Immunology, University of North Carolina/Chapel Hill, North Carolina/Etats-Unis (3 aut., 4 aut., 7 aut.); Novartis Vaccines, Via Fiorentina 1/53100 Siena/Italie (5 aut.)
DT :	Publication en série; Niveau analytique
SO :	Journal of virology; ISSN 0022-538X; Etats-Unis; Da. 2008; Vol. 82; No. 7; Pp. 3220-3235; Bibl. 57 ref.
LA :	Anglais
EA :	Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in 2002, and detailed phylogenetic and epidemiological analyses have suggested that it originated from animals. The spike (S) glycoprotein has been identified as a major component of protective immunity, and 23 different amino acid changes were noted during the expanding epidemic. Using a panel of SARS-CoV recombinants bearing the S glycoproteins from isolates representing the zoonotic and human early, middle, and late phases of the epidemic, we identified 23 monoclonal antibodies (MAbs) with neutralizing activity against one or multiple SARS-CoV spike variants and determined the presence of at least six distinct neutralizing profiles in the SARS-CoV S glycoprotein. Four of these MAbs showed cross-neutralizing activity against all human and zoonotic S variants in vitro, and at least three of these were mapped in distinct epitopes using escape mutants, structure analyses, and competition assays. These three MAbs (S109.8, S227.14, and S230.15) were tested for use in passive vaccination studies using lethal SARS-CoV challenge models for young and senescent mice with four different homologous and heterologous SARS-CoV S variants. Both S227.14 and S230.15 completely protected young and old mice from weight loss and virus replication in the lungs for all viruses tested, while S109.8 completely protected mice from weight loss and clinical signs in the presence of viral titers. We conclude that a single human MAb can confer broad protection against lethal challenge with multiple zoonotic and human SARS-CoV isolates, and we identify a robust cocktail formulation that targets distinct epitopes and minimizes the likely generation of escape mutants.
CC :	002A05C10; 002A05C07
FD :	Homme; Coronavirus; Protection croisée; Anticorps neutralisant; Anticorps monoclonal; Aigu; Virologie
FG :	Coronaviridae; Nidovirales; Virus
ED :	Human; Coronavirus; Cross protection; Neutralizing antibody; Monoclonal antibody; Acute; Virology
EG :	Coronaviridae; Nidovirales; Virus
SD :	Hombre; Coronavirus; Protección cruzada; anticuerpo neutralizante; Anticuerpo monoclonal; Agudo; Virología
LO :	INIST-13592.354000183723680050
ID :	08-0181246

Links to Exploration step

Pascal:08-0181246

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge</title>
<author><name sortKey="Rockx, Barry" sort="Rockx, Barry" uniqKey="Rockx B" first="Barry" last="Rockx">Barry Rockx</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Epidemiology, University of North Carolina</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Corti, Davide" sort="Corti, Davide" uniqKey="Corti D" first="Davide" last="Corti">Davide Corti</name>
<affiliation><inist:fA14 i1="02"><s1>Institute for Research in Biomedicine</s1>
<s2>Bellinzona</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Donaldson, Eric" sort="Donaldson, Eric" uniqKey="Donaldson E" first="Eric" last="Donaldson">Eric Donaldson</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Microbiology and Immunology, University of North Carolina</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sheahan, Timothy" sort="Sheahan, Timothy" uniqKey="Sheahan T" first="Timothy" last="Sheahan">Timothy Sheahan</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Microbiology and Immunology, University of North Carolina</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stadler, Konrad" sort="Stadler, Konrad" uniqKey="Stadler K" first="Konrad" last="Stadler">Konrad Stadler</name>
<affiliation><inist:fA14 i1="04"><s1>Novartis Vaccines, Via Fiorentina 1</s1>
<s2>53100 Siena</s2>
<s3>ITA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lanzavecchia, Antonio" sort="Lanzavecchia, Antonio" uniqKey="Lanzavecchia A" first="Antonio" last="Lanzavecchia">Antonio Lanzavecchia</name>
<affiliation><inist:fA14 i1="02"><s1>Institute for Research in Biomedicine</s1>
<s2>Bellinzona</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Baric, Ralph" sort="Baric, Ralph" uniqKey="Baric R" first="Ralph" last="Baric">Ralph Baric</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Epidemiology, University of North Carolina</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Microbiology and Immunology, University of North Carolina</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0181246</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0181246 INIST</idno>
<idno type="RBID">Pascal:08-0181246</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000299</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge</title>
<author><name sortKey="Rockx, Barry" sort="Rockx, Barry" uniqKey="Rockx B" first="Barry" last="Rockx">Barry Rockx</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Epidemiology, University of North Carolina</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Corti, Davide" sort="Corti, Davide" uniqKey="Corti D" first="Davide" last="Corti">Davide Corti</name>
<affiliation><inist:fA14 i1="02"><s1>Institute for Research in Biomedicine</s1>
<s2>Bellinzona</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Donaldson, Eric" sort="Donaldson, Eric" uniqKey="Donaldson E" first="Eric" last="Donaldson">Eric Donaldson</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Microbiology and Immunology, University of North Carolina</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sheahan, Timothy" sort="Sheahan, Timothy" uniqKey="Sheahan T" first="Timothy" last="Sheahan">Timothy Sheahan</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Microbiology and Immunology, University of North Carolina</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stadler, Konrad" sort="Stadler, Konrad" uniqKey="Stadler K" first="Konrad" last="Stadler">Konrad Stadler</name>
<affiliation><inist:fA14 i1="04"><s1>Novartis Vaccines, Via Fiorentina 1</s1>
<s2>53100 Siena</s2>
<s3>ITA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lanzavecchia, Antonio" sort="Lanzavecchia, Antonio" uniqKey="Lanzavecchia A" first="Antonio" last="Lanzavecchia">Antonio Lanzavecchia</name>
<affiliation><inist:fA14 i1="02"><s1>Institute for Research in Biomedicine</s1>
<s2>Bellinzona</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Baric, Ralph" sort="Baric, Ralph" uniqKey="Baric R" first="Ralph" last="Baric">Ralph Baric</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Epidemiology, University of North Carolina</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Microbiology and Immunology, University of North Carolina</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of virology</title>
<title level="j" type="abbreviated">J. virol.</title>
<idno type="ISSN">0022-538X</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of virology</title>
<title level="j" type="abbreviated">J. virol.</title>
<idno type="ISSN">0022-538X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acute</term>
<term>Coronavirus</term>
<term>Cross protection</term>
<term>Human</term>
<term>Monoclonal antibody</term>
<term>Neutralizing antibody</term>
<term>Virology</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Homme</term>
<term>Coronavirus</term>
<term>Protection croisée</term>
<term>Anticorps neutralisant</term>
<term>Anticorps monoclonal</term>
<term>Aigu</term>
<term>Virologie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in 2002, and detailed phylogenetic and epidemiological analyses have suggested that it originated from animals. The spike (S) glycoprotein has been identified as a major component of protective immunity, and 23 different amino acid changes were noted during the expanding epidemic. Using a panel of SARS-CoV recombinants bearing the S glycoproteins from isolates representing the zoonotic and human early, middle, and late phases of the epidemic, we identified 23 monoclonal antibodies (MAbs) with neutralizing activity against one or multiple SARS-CoV spike variants and determined the presence of at least six distinct neutralizing profiles in the SARS-CoV S glycoprotein. Four of these MAbs showed cross-neutralizing activity against all human and zoonotic S variants in vitro, and at least three of these were mapped in distinct epitopes using escape mutants, structure analyses, and competition assays. These three MAbs (S109.8, S227.14, and S230.15) were tested for use in passive vaccination studies using lethal SARS-CoV challenge models for young and senescent mice with four different homologous and heterologous SARS-CoV S variants. Both S227.14 and S230.15 completely protected young and old mice from weight loss and virus replication in the lungs for all viruses tested, while S109.8 completely protected mice from weight loss and clinical signs in the presence of viral titers. We conclude that a single human MAb can confer broad protection against lethal challenge with multiple zoonotic and human SARS-CoV isolates, and we identify a robust cocktail formulation that targets distinct epitopes and minimizes the likely generation of escape mutants.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0022-538X</s0>
</fA01>
<fA03 i2="1"><s0>J. virol.</s0>
</fA03>
<fA05><s2>82</s2>
</fA05>
<fA06><s2>7</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>ROCKX (Barry)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>CORTI (Davide)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>DONALDSON (Eric)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>SHEAHAN (Timothy)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>STADLER (Konrad)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>LANZAVECCHIA (Antonio)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>BARIC (Ralph)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Epidemiology, University of North Carolina</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Institute for Research in Biomedicine</s1>
<s2>Bellinzona</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Microbiology and Immunology, University of North Carolina</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Novartis Vaccines, Via Fiorentina 1</s1>
<s2>53100 Siena</s2>
<s3>ITA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>3220-3235</s1>
</fA20>
<fA21><s1>2008</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>13592</s2>
<s5>354000183723680050</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>57 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0181246</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of virology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in 2002, and detailed phylogenetic and epidemiological analyses have suggested that it originated from animals. The spike (S) glycoprotein has been identified as a major component of protective immunity, and 23 different amino acid changes were noted during the expanding epidemic. Using a panel of SARS-CoV recombinants bearing the S glycoproteins from isolates representing the zoonotic and human early, middle, and late phases of the epidemic, we identified 23 monoclonal antibodies (MAbs) with neutralizing activity against one or multiple SARS-CoV spike variants and determined the presence of at least six distinct neutralizing profiles in the SARS-CoV S glycoprotein. Four of these MAbs showed cross-neutralizing activity against all human and zoonotic S variants in vitro, and at least three of these were mapped in distinct epitopes using escape mutants, structure analyses, and competition assays. These three MAbs (S109.8, S227.14, and S230.15) were tested for use in passive vaccination studies using lethal SARS-CoV challenge models for young and senescent mice with four different homologous and heterologous SARS-CoV S variants. Both S227.14 and S230.15 completely protected young and old mice from weight loss and virus replication in the lungs for all viruses tested, while S109.8 completely protected mice from weight loss and clinical signs in the presence of viral titers. We conclude that a single human MAb can confer broad protection against lethal challenge with multiple zoonotic and human SARS-CoV isolates, and we identify a robust cocktail formulation that targets distinct epitopes and minimizes the likely generation of escape mutants.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05C10</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002A05C07</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Homme</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Human</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Hombre</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Protection croisée</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Cross protection</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Protección cruzada</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Anticorps neutralisant</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Neutralizing antibody</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>anticuerpo neutralizante</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Anticorps monoclonal</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Monoclonal antibody</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Anticuerpo monoclonal</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Aigu</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Acute</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Agudo</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Virologie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Virology</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Virología</s0>
<s5>09</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fN21><s1>112</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 08-0181246 INIST</NO>
<ET>Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge</ET>
<AU>ROCKX (Barry); CORTI (Davide); DONALDSON (Eric); SHEAHAN (Timothy); STADLER (Konrad); LANZAVECCHIA (Antonio); BARIC (Ralph)</AU>
<AF>Department of Epidemiology, University of North Carolina/Chapel Hill, North Carolina/Etats-Unis (1 aut., 7 aut.); Institute for Research in Biomedicine/Bellinzona/Suisse (2 aut., 6 aut.); Department of Microbiology and Immunology, University of North Carolina/Chapel Hill, North Carolina/Etats-Unis (3 aut., 4 aut., 7 aut.); Novartis Vaccines, Via Fiorentina 1/53100 Siena/Italie (5 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Journal of virology; ISSN 0022-538X; Etats-Unis; Da. 2008; Vol. 82; No. 7; Pp. 3220-3235; Bibl. 57 ref.</SO>
<LA>Anglais</LA>
<EA>Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in 2002, and detailed phylogenetic and epidemiological analyses have suggested that it originated from animals. The spike (S) glycoprotein has been identified as a major component of protective immunity, and 23 different amino acid changes were noted during the expanding epidemic. Using a panel of SARS-CoV recombinants bearing the S glycoproteins from isolates representing the zoonotic and human early, middle, and late phases of the epidemic, we identified 23 monoclonal antibodies (MAbs) with neutralizing activity against one or multiple SARS-CoV spike variants and determined the presence of at least six distinct neutralizing profiles in the SARS-CoV S glycoprotein. Four of these MAbs showed cross-neutralizing activity against all human and zoonotic S variants in vitro, and at least three of these were mapped in distinct epitopes using escape mutants, structure analyses, and competition assays. These three MAbs (S109.8, S227.14, and S230.15) were tested for use in passive vaccination studies using lethal SARS-CoV challenge models for young and senescent mice with four different homologous and heterologous SARS-CoV S variants. Both S227.14 and S230.15 completely protected young and old mice from weight loss and virus replication in the lungs for all viruses tested, while S109.8 completely protected mice from weight loss and clinical signs in the presence of viral titers. We conclude that a single human MAb can confer broad protection against lethal challenge with multiple zoonotic and human SARS-CoV isolates, and we identify a robust cocktail formulation that targets distinct epitopes and minimizes the likely generation of escape mutants.</EA>
<CC>002A05C10; 002A05C07</CC>
<FD>Homme; Coronavirus; Protection croisée; Anticorps neutralisant; Anticorps monoclonal; Aigu; Virologie</FD>
<FG>Coronaviridae; Nidovirales; Virus</FG>
<ED>Human; Coronavirus; Cross protection; Neutralizing antibody; Monoclonal antibody; Acute; Virology</ED>
<EG>Coronaviridae; Nidovirales; Virus</EG>
<SD>Hombre; Coronavirus; Protección cruzada; anticuerpo neutralizante; Anticuerpo monoclonal; Agudo; Virología</SD>
<LO>INIST-13592.354000183723680050</LO>
<ID>08-0181246</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000299 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000299 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:08-0181246
   |texte=   Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge

Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri